SERS Chip Diagnoses Heart Attacks in Five Minutes - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

SERS Chip Diagnoses Heart Attacks in Five Minutes

New metasurface-based blood test detects cardiac biomarkers in just minutes, offering faster diagnosis in clinical settings

  • October 29, 2024

  • 3 min

Share

Objective:

To develop a rapid blood test for diagnosing heart attacks using a plasmonic metasurface and surface-enhanced Raman spectroscopy (SERS).

Approach:
  • Technology Development: A metasurface-enhanced chip was created to amplify signals for detecting cardiac biomarkers in blood samples.
  • Biomarker Detection: The system detects key biomarkers like CK-MB, Mb, and cTnI in 5–7 minutes, significantly faster than traditional methods.
  • Signal Measurement: The technology tracks frequency shifts in the SERS signal to accurately measure multiple biomarkers simultaneously.
Key Findings:
  • The new test can diagnose heart attacks in 5–7 minutes.
  • It detects biomarkers at ultra-low concentrations with high sensitivity.
  • The approach mitigates signal fluctuations common in traditional SERS methods.
Interpretation:

Limitations:
  • Further refinement of the device is needed.
  • Clinical trials must be expanded to evaluate performance across diverse patient populations.
Conclusion:

Sources:

Original Source(s)

SERS Chip Diagnoses Heart Attacks in Five Minutes

  • October 29, 2024

Related Content

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

When Heart Failure Treatment Isn’t Enough: Signs It’s Time to Refer for Advanced Heart Failure Care

Advanced heart failure does not always present as a single defining event. Referring physicians may instead notice a pattern of worsening symptoms, recurrent hospitalizations or increasing difficulty maintaining a patient’s clinical stability.

  • by

  • August 28, 2026

  • 6 min
Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK)